Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Regardless of adherence to weekly Wegovy (semaglutide) injections, adults with obesity ... researchers estimated weight loss would be 20.7% for the 7.2 milligram group, 17.5% for the 2.4 milligram ...

“Taking these medications puts individuals at risk of everything from allergic reactions to uncontrolled blood sugar levels, ...

The National Pharmacy Association is calling for tougher rules in the market, saying people with a history of eating ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, ...

A study has suggested that weight-loss injections may be linked to broader ... discovered that participants who used drugs such as Wegovy and Ozempic had a lower risk of 42 health conditions ...